



RECEIVED
AUG 13 2003
TECH CENTER 1653/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hastings et al.

Docket No.: PF487

Application No.: 09/466,778

Group Art Unit: 1653

Filed: December 20, 1999

Examiner: R. Mitra

For: Novel Hyaluronan-Binding Protein Encoding
Genes

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 C.F.R. 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AG-AP listed on the attached Form PTO/SB/08A. A copy of each of the references is enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the PTO's duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such

COMMUNICATIONS SECTION
AUG 13 2003
1653/2900

references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this 2nd Supplemental Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a Notice of Allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal, with the appropriate fee. The Commissioner is also authorized to charge any additional required fee or credit any overpayment in connection with this submission to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: _____

August 8, 2003

By _____

Mark J. Hyman

Registration No.: 46,789

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(240) 314-1224



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/466,778
				Filing Date	December 20, 1999
				First Named Inventor	Gregg A. Hastings
				Art Unit	1653
				Examiner Name	R. Mitra
Sheet	1	of	1	Attorney Docket Number	PF487

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	AG	WO01/81544-A2	11-01-2001	WEIGEL et al.		
	AH	WO02/086093-A2	10-31-2002	WEIGEL et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AI	POLITZ et al., "Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues," Biochem. J. 362:155-164 (2002).			
	AJ	ZHOU et al., "Purification and molecular identification of the human hyaluronan receptor for endocytosis," Glycobiology 13(5):339-349 (2003).			
	AK	OERTLI et al., "Mechanisms of hyaluronan-induced up-regulation of ICAM-1 and VCAM-1 expression by murine kidney tubular epithelial cells: hyaluronan triggers cell adhesion molecule expression through a mechanism involving activation of nuclear factor-KB and activating protein-1," J of Immunology 161:3431-7 (1998).			
	AL	TSIFRINA et al., "Identification and characterization of three cDNAs that encode putative novel hyaluronan-binding proteins, including an endothelial cell-specific hyaluronan receptor," Am J Pathol 155(5):1625-33 (1999).			
	AM	MCCARTY et al., "Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis," Med Hypothesis. 50(6):507-10 (1998).			
	AN	UEBELHART et al., "Effects of hyaluronic acid on cartilage degradation," Curr Opin Rheumatol. 11(5):427-35 (1999).			
	AO	NAOR et al., "CD44: structure, function, and association with the malignant process," Adv Cancer Res. 71:241-319 (1997).			
	AP	WISNIEWSKI et al., TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity," Cytokine Growth Factor Rev. 8(2):143-156 (1997).			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--